Japanese Randomised Trial Will Evaluate Abbott’s Absorb™ Bioresorbable Vascular Scaffold

Abbott is commencing a trial to study its innovative “Dissolving” Heart stent compared to its own drug-eluting stents in patients with Coronary Artery Disease.

Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the Absorb™ Bioresorbable Vascular Scaffold (via PR Newswire)

– Trial to Study the Innovative “Dissolving” Heart Device Compared to Abbott’s Market-Leading Drug Eluting Stents in Patients with Coronary Artery Disease in Japan ABBOTT PARK, Ill., June 11, 2013 /PRNewswire/ — Abbott (NYSE: ABT) today announced that it has initiated the ABSORB Japan randomized…

published: June 11, 2013 in: Abbott, Cardio, Clinical Studies/Trials

Most read

Latest

^